#KIF18A

Accent Therapeutics Unveils Promising Data on Innovative KIF18A Inhibitor ATX-295 at AACR 2026 Accent Therapeutics showcased strong preclinical data for ATX-295, a promising KIF18A inhibitor, at the AACR Annual Meeting 2026, highlighting its anti-cancer potential.

Accent Therapeutics Unveils Promising Data on Innovative KIF18A Inhibitor ATX-295 at AACR 2026 #USA #San_Diego #Accent_Therapeutics #ATX-295 #KIF18A

Accent Therapeutics to Share Breakthrough Data on Cancer Treatment ATX-295 at Major Conference Accent Therapeutics is set to unveil promising preclinical findings on ATX-295, a KIF18A inhibitor aimed at treating various cancer types, at the upcoming AACR Annual Meeting.

Accent Therapeutics to Share Breakthrough Data on Cancer Treatment ATX-295 at Major Conference #USA #San_Diego #Accent_Therapeutics #ATX-295 #KIF18A

#ASCO2025

🔥 Drug development track
🕑 2:45pm

📉 Exciting science to be presented❗

New drugs into #trials
💉 Biespecific+/- ADC
💥 ADC+ IO
🎯 #KRASG12D
🧬 New small mol #KIF18A
🩸⚒️ More #ctDNA and new #IA

@oncoalert.bsky.social
@myesmo.bsky.social

👇🏽 My TOP 10 for #drugdevelopment